Home » Stocks » ABEO

Abeona Therapeutics Inc. (ABEO)

Stock Price: $1.91 USD -0.07 (-3.54%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.92 +0.01 (0.52%) Jan 15, 7:56 PM
Market Cap 188.19M
Revenue (ttm) 7.00M
Net Income (ttm) -84.84M
Shares Out 93.77M
EPS (ttm) -1.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.91
Previous Close $1.98
Change ($) -0.07
Change (%) -3.54%
Day's Open 1.99
Day's Range 1.88 - 2.07
Day's Volume 2,165,849
52-Week Range 1.02 - 4.08

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 days ago

Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.

GlobeNewsWire - 3 weeks ago

NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing ...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.

Benzinga - 2 months ago

Abeona Therapeutics Inc's (NASDAQ: ABEO) stock does not reflect the company's in-house manufacturing capabilities and pipeline, according to Cantor Fitzgerald. The Abeona Therapeutics Analyst:...

Zacks Investment Research - 2 months ago

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of 38.46% and 0.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 2 months ago

Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET

GlobeNewsWire - 2 months ago

NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Sen...

GlobeNewsWire - 3 months ago

Steven H. Rouhandeh Appointed as Chairman of the Board of Directors

GlobeNewsWire - 3 months ago

NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executi...

GlobeNewsWire - 4 months ago

NEW YORK and CLEVELAND, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will ...

GlobeNewsWire - 4 months ago

NEW YORK and CLEVELAND and DALLAS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a...

GlobeNewsWire - 5 months ago

Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs

GlobeNewsWire - 6 months ago

NEW YORK and CLEVELAND, July 10, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two poster present...

Zacks Investment Research - 6 months ago

Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.

GlobeNewsWire - 6 months ago

To lead Abeona’s commercial organization, EB-101 commercialization planning and pre-commercial strategy for AAV-based gene therapy programs To lead Abeona’s commercial organization, EB-101 com...

GlobeNewsWire - 6 months ago

NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its c...

GlobeNewsWire - 6 months ago

NEW YORK and CLEVELAND, June 18, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts rela...

GlobeNewsWire - 6 months ago

NEW YORK and CLEVELAND, June 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced Board of Director appoi...

Zacks Investment Research - 7 months ago

Is (ABEO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

Abeona Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

Zacks Investment Research - 8 months ago

Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.

GlobeNewsWire - 8 months ago

NEW YORK and CLEVELAND, April 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced it granted options to ...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.

GlobeNewsWire - 8 months ago

Company appoints experienced industry leaders Brian Pereira as Executive Chairman and Shawn Tomasello as Independent Board Member Company appoints experienced industry leaders Brian Pereira as...

Zacks Investment Research - 8 months ago

Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.

Zacks Investment Research - 9 months ago

Abeona Therapeutics (ABEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 9 months ago

NEW YORK and CLEVELAND, March 27, 2020 (GLOBE NEWSWIRE) -- The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Many institutions and their brave staf...

Zacks Investment Research - 9 months ago

Abeona Therapeutics (ABEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 9 months ago

Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissu...

GlobeNewsWire - 9 months ago

Majority of potential study participants have been pre-screened

The Motley Fool - 10 months ago

Can these high-flying biotech stocks keep up their sizzling momentum?

Other stocks mentioned: AVDL, RCUS
Zacks Investment Research - 10 months ago

Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.

Zacks Investment Research - 10 months ago

The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

Other stocks mentioned: APLT, EBF, ONTX, PTI
Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.

GlobeNewsWire - 11 months ago

Neurocognitive development of young MPS IIIA patients preserved up to two years post ABO-102 treatment

GlobeNewsWire - 1 year ago

NEW YORK and CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States ...

GlobeNewsWire - 1 year ago

Study open for enrollment and patient screening underway at Stanford University

Seeking Alpha - 1 year ago

Abeona Therapeutics: Speculative Buy After Financing

GlobeNewsWire - 1 year ago

NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its unde...

The Motley Fool - 1 year ago

The small-cap company announced the pricing of a public stock offering.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.

GlobeNewsWire - 1 year ago

NEW YORK and CLEVELAND, Dec. 20, 2019 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its pub...

GlobeNewsWire - 1 year ago

PRIME is sixth regulatory designation for the ABO-102 clinical program PRIME is sixth regulatory designation for the ABO-102 clinical program

GlobeNewsWire - 1 year ago

NEW YORK and CLEVELAND, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offe...

GlobeNewsWire - 1 year ago

FDA removes clinical hold; Company may proceed with VIITAL™ study

GlobeNewsWire - 1 year ago

NEW YORK and CLEVELAND, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the presentations of da...

GlobeNewsWire - 1 year ago

Sustained wound healing and favorable safety profile observed at three years post-treatment

Benzinga - 1 year ago

Abeona Therapeutics Inc (NASDAQ: ABEO)'s market capitalization was growing by about two-thirds Tuesday following an announcement concerning the exploration of strategic options.

Seeking Alpha - 1 year ago

Abeona Therapeutics Inc. (ABEO) CEO João Siffert on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -25.64% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the...

About ABEO

Abeona Therapeutics, a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten diseas... [Read more...]

Industry
Biotechnology
IPO Date
Sep 19, 1980
CEO
Jeffrey Davis
Employees
88
Stock Exchange
NASDAQ
Ticker Symbol
ABEO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is 5.00, which is an increase of 161.78% from the latest price.

Price Target
$5.00
(161.78% upside)
Analyst Consensus: Buy